Methods and compositions for treating disorders

Patent metadata

Field	Value
Publication number	US-10064963-B2
Application number	US-201314369353-A
Country	US
Kind code	B2
Filing date	Jan 7, 2013
Priority date	Jan 9, 2012
Publication date	Sep 4, 2018
Grant date	Sep 4, 2018

Abstract

The present disclosure relates to a method of treating, ameliorating or preventing a disorder by blocking the signaling pathway of c-Met, wherein said method comprises the step of administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof. In addition, the present disclosure relates to a diagnostic composition suitable for use in, e.g., an immuno-imaging technique to detect the presence of c-Met as well as the uses thereof.

First claim

The invention claimed is:

1. A lipocalin mutein having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2, wherein sequence identity is determined by dividing the number of identical residues by the total number of residues and multiplying the product by 100, wherein said mutein is capable of inducing internalization of c-Met from the surface of a cell that expresses c-Met, and wherein the mutein comprises, at positions 26-34, 56-58, 80, 83, 104-106, and 108 corresponding to the linear polypeptide sequence of the mature human tear lipocalin (SEQ ID NO: 3), the same set of amino acid residues that the muteins set forth in SEQ ID NO: 1 or SEQ ID NO: 2 have at the respective positions.

2. The mutein of claim 1 , wherein the mutein is conjugated to a compound that extends the serum half-life of the mutein, wherein compound is selected from the group consisting of a polyalkylene glycol molecule, a hydroxyethyl starch, a protein domain, a Fc part of an immunoglobulin, a CH3 domain of an immunoglobulin, a CH4 domain of an immunoglobulin, an albumin-binding peptide, and an albumin-binding protein.

3. The mutein of claim 1 , wherein the mutein lacks at least one N-terminal or C-terminal amino acid of SEQ ID NO: 1 or SEQ ID NO: 2.

4. A pharmaceutical composition comprising the mutein of claim 1 .

5. The pharmaceutical composition of claim 4 , which is formulated for parenteral administration.

6. The pharmaceutical composition of claim 4 , which is formulated for enteral administration.

7. The mutein of claim 1 , wherein the mutein comprises the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2.

8. The mutein of claim 1 , wherein the mutein comprises the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 except the first four N-terminal amino acid residues and the last two C-terminal amino acid residues.

Assignees

• Pieris Ag
• Pieris Pharmaceuticals Gmbh

Inventors

• Olwill Shane
• Gille Hendrik
• Audoly Laurent
• Hinner Marlon
• De Vries Elisabeth
• Terwisscha Van Scheltinga Anton G T

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• A61K38/16

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title